FIELD: biotechnology; medicine; agriculture.
SUBSTANCE: invention refers to genetic engineering and can be used in biotechnology, medicine and agriculture to develop gene therapy preparations. Gene-therapy DNA vector based on the gene-therapy DNA vector VTvaf17, having a target gene selected from the group of genes BMP-2, BMP-7, LMP-1, NELL-1, is created to increase the level of expression of this target gene in the human and animal body, wherein the gene-therapy DNA vector VTvaf17-BMP-2, or VTvaf17-BMP-7, or VTvaf17-LMP-1, or VTvaf17-NELL-1 has the nucleotide sequence SEQ ID No. 1, or SEQ ID No. 2, or SEQ ID No. 3, or SEQ ID No. 4, respectively. Each of the created gene-therapy DNA vectors: VTvaf17-BMP-2, or VTvaf17-BMP-7, or VTvaf17-LMP-1, or VTvaf17 NELL-1 due to the limited size of the vector part VTvaf17, not exceeding 3200 base pairs, is able to efficiently penetrate into cells and to express a target gene cloned in it, selected from a group of genes BMP-2, BMP-7, LMP-1, NELL-1 respectively.
EFFECT: gene-therapy DNA-vector contains no nucleotide sequences of viral origin and antibiotic-resistant genes are absent, providing the possibility of its safe application for genetic therapy of human and animals.
14 cl, 15 dwg, 20 ex
